OVID - Ovid Therapeutics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
OVID price evolution
OVID
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $28.97 | $59.37 | $73.55 | $64.98 |
| Short term investments | $78.79 | $29.64 | $24.89 | $54.67 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $109.6 | $91.71 | $102.17 | $119.52 |
| Long term investments | $17.63 | $16.12 | $16.47 | $5.98 |
| Property, plant & equipment | $14.66 | $15.01 | $15.37 | $15.72 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $34.43 | $33.32 | $34.06 | $23.85 |
| Total investments | $96.42 | $45.76 | $41.36 | $60.65 |
| Total assets | $144.03 | $125.03 | $136.23 | $143.37 |
| Current liabilities | ||||
| Accounts payable | $3.7 | $1.22 | $3.76 | $1.83 |
| Deferred revenue | ||||
| Short long term debt | $1.25 | $1.22 | $0.94 | $0.8 |
| Total current liabilities | $11.47 | $8.66 | $10.14 | $6.72 |
| Long term debt | $44.76 | $15.07 | $15.39 | $15.7 |
| Total noncurrent liabilities | $44.76 | $15.07 | $15.39 | $15.7 |
| Total debt | $46 | $16.3 | $16.33 | $16.5 |
| Total liabilities | $56.23 | $23.74 | $25.53 | $22.42 |
| Shareholders' equity | ||||
| Retained earnings | -$277.87 | -$262.54 | -$251.29 | -$238.88 |
| Other shareholder equity | $0 | -$0 | $0.01 | $0.01 |
| Total shareholder equity | $87.8 | $101.29 | $110.7 | $120.95 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $28.97 | $2.85 | $189.73 | $72.03 |
| Short term investments | $78.79 | $84.13 | ||
| Net receivables | $0.14 | |||
| Inventory | ||||
| Total current assets | $109.6 | $131.38 | $190.48 | $74.84 |
| Long term investments | $17.63 | $5.62 | $1.63 | |
| Property, plant & equipment | $14.66 | $16.07 | $0.24 | $0.14 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $34.43 | $23.89 | $4.07 | $1.08 |
| Total investments | $96.42 | $89.76 | $1.63 | |
| Total assets | $144.03 | $155.27 | $194.54 | $75.93 |
| Current liabilities | ||||
| Accounts payable | $3.7 | $1.95 | $7.13 | $7.88 |
| Deferred revenue | $12.38 | |||
| Short long term debt | $1.25 | $0.53 | ||
| Total current liabilities | $11.47 | $6.99 | $14.8 | $22.06 |
| Long term debt | $44.76 | $16 | $0.06 | |
| Total noncurrent liabilities | $44.76 | $16 | $10.23 | |
| Total debt | $46 | $16.54 | ||
| Total liabilities | $56.23 | $22.99 | $14.8 | $32.29 |
| Shareholders' equity | ||||
| Retained earnings | -$277.87 | -$225.53 | -$171.36 | -$294.19 |
| Other shareholder equity | $0 | -$0.04 | $0 | |
| Total shareholder equity | $87.8 | $132.27 | $179.75 | $43.63 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.14 | $0.11 | $0.07 | $0.07 |
| Cost of revenue | ||||
| Gross Profit | $0.14 | $0.11 | $0.07 | $0.07 |
| Operating activities | ||||
| Research & development | $10.64 | $5.33 | $6 | $6.61 |
| Selling, general & administrative | $7.69 | $6.81 | $8.25 | $8.34 |
| Total operating expenses | $18.33 | $12.14 | $14.25 | $14.96 |
| Operating income | -$18.19 | -$12.03 | -$14.17 | -$14.89 |
| Income from continuing operations | ||||
| EBIT | -$15.32 | -$11.25 | -$12.41 | -$13.36 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$15.32 | -$11.25 | -$12.41 | -$13.36 |
| Income (for common shares) | -$15.32 | -$11.25 | -$12.41 | -$13.36 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.39 | $1.5 | $208.38 | $12.62 |
| Cost of revenue | ||||
| Gross Profit | $0.39 | $1.5 | $208.38 | $12.62 |
| Operating activities | ||||
| Research & development | $28.59 | $24.62 | $46.94 | $63.42 |
| Selling, general & administrative | $31.09 | $32.43 | $37.23 | $30.63 |
| Total operating expenses | $59.67 | $57.05 | $84.17 | $94.05 |
| Operating income | -$59.28 | -$55.55 | $124.21 | -$81.43 |
| Income from continuing operations | ||||
| EBIT | -$52.34 | -$54.17 | $124.16 | -$81.04 |
| Income tax expense | $1.33 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$52.34 | -$54.17 | $122.83 | -$81.04 |
| Income (for common shares) | -$52.34 | -$54.17 | $122.83 | -$81.04 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$15.32 | -$11.25 | -$12.41 | -$13.36 |
| Operating activities | ||||
| Depreciation | $0.4 | $0.4 | $0.39 | $0.4 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.79 | $1.63 | $1.95 | $1.92 |
| Total cash flows from operations | -$11.91 | -$10.05 | -$11.71 | -$12.11 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.01 | -$0.01 | -$0.01 |
| Investments | -$48.51 | -$4.35 | $20.18 | $30.24 |
| Total cash flows from investing | -$48.52 | -$4.36 | $20.07 | $30.23 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.22 | $0.21 | $0.07 |
| Net borrowings | $30 | |||
| Total cash flows from financing | $30.03 | $0.22 | $0.21 | $0.07 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$30.4 | -$14.19 | $8.57 | $18.18 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$52.34 | -$54.17 | $122.83 | -$81.04 |
| Operating activities | ||||
| Depreciation | $1.6 | $1.38 | $0.24 | $0.31 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.29 | $6.56 | $5.05 | $7.53 |
| Total cash flows from operations | -$45.78 | -$55.23 | $118.61 | -$51.58 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$1.22 | -$0.18 | -$0.13 |
| Investments | -$2.44 | -$86.46 | -$1.63 | $35.04 |
| Total cash flows from investing | -$2.58 | -$87.88 | -$1.82 | $34.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.54 | $0.18 | $0.9 | $47.24 |
| Net borrowings | $30 | |||
| Total cash flows from financing | $30.54 | $0.18 | $0.9 | $47.07 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$17.83 | -$142.93 | $117.69 | $30.14 |
News
Fundamentals
| Market cap | $212.08M |
|---|---|
| Enterprise value | $229.11M |
| Shares outstanding | 70.69M |
| Revenue | $391.69K |
|---|---|
| EBITDA | -$50.74M |
| EBIT | -$52.34M |
| Net Income | -$52.34M |
| Revenue Q/Q | 205.88% |
| Revenue Y/Y | -73.93% |
| P/E ratio | -4.05 |
|---|---|
| EV/Sales | 584.91 |
| EV/EBITDA | -4.52 |
| EV/EBIT | -4.38 |
| P/S ratio | 541.43 |
| P/B ratio | 2.42 |
| Book/Share | 1.24 |
| Cash/Share | 0.41 |
| EPS | -$0.74 |
|---|---|
| ROA | -38.16% |
| ROE | -49.76% |
| Debt/Equity | 0.64 |
|---|---|
| Net debt/EBITDA | -0.54 |
| Current ratio | 9.55 |
| Quick ratio | 9.55 |